Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06646289 · ClinicalTrials.gov registry record · Phase 2
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
A Phase 2 study of X-Linked Retinitis Pigmentosa, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT06646289 is a Phase 2 study of X-Linked Retinitis Pigmentosa that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 24 participants, below the 55-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (56% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06646289, a Phase 2 study of X-Linked Retinitis Pigmentosa, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
Conditions Studied
Interventions
- BIOLOGICAL AAV5-hRKp.RPGR
- OTHER No intervention (Follow-Up assessment)
Study Locations (3)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Other
- Moorfields Eye Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2030-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06646289
The ClinicalTrials.gov registry entry for NCT06646289 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (56% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with X-Linked Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which AAV5-hRKp.RPGR is the first listed.
NCT06646289 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Michigan, Other.
Frequently Asked Questions
What is clinical trial NCT06646289 about?
NCT06646289 is a clinical study titled "A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)". The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
What is the current status of trial NCT06646289?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-10-10. Estimated completion is 2030-10-24.
What conditions does trial NCT06646289 study?
This clinical trial studies the following conditions: X-Linked Retinitis Pigmentosa.
What interventions are being tested in trial NCT06646289?
The interventions under investigation include: AAV5-hRKp.RPGR (BIOLOGICAL), No intervention (Follow-Up assessment) (OTHER).
Who is sponsoring clinical trial NCT06646289?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06646289 being conducted?
This trial has 3 study locations across Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-Linked Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
ACTIVE NOT RECRUITING · Phase 2
-
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
ACTIVE NOT RECRUITING · Phase 1
-
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Follow-up Gene Therapy Study for RPGR- XLRP
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.